Lycera announced the closing of a $36M Series A round of funding. The company is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, has received $10 million as a first tranche of the financing and will receive the remainder of the proceeds in two tranches as specific milestones are met. InterWest Partners, ARCH Venture Partners and Clarus Ventures co-led the financing. EDF Ventures, which led a seed financing in November 2006, is also participating.
They are focused on the discovery and development of small-molecule immunomodulators for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, lupus erythematosis, inflammatory bowel disease and transplant rejection. Originally founded by Dr. Gary Glick as a spin-out of the University of Michigan, Lycera is developing drug candidates that target two novel therapeutic pathways and have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. Visit www.lycera.com for more information.
Lycera also announced that it has expanded its development initiatives for small-molecule immunomodulators through the addition of a program targeting the Th17 pathway discovered by Dan Littman, M.D., Ph.D. Dr. Littman, the Helen L. and Martin S. Kimmel.
Clarus’s Dr. Leiden added, “Lycera combines two of the most exciting, new small-molecule approaches for treating autoimmune diseases. The company will leverage the complementary expertise and discoveries of Dr. Glick in medicinal chemistry with those of Dr. Littman in immunology and the Th17 pathway. The Series A financing will enable Lycera to advance its first drug candidate through Phase II proof-of-concept studies and a second candidate into Phase I clinical trials.”
Lycera Closes $36 Million Series A
(Via Biospace)
Synageva Nets $30M
Synageva BioPharma announced the first closing of a financing raising $30 million. The round was led by Baker Brothers Investments. Other investors participating in the ...
Shorting Dendreon
In retrospect... not a good idea. Already up 189% today presumably after the short squeeze.
Layoffs and Such
I promise... they posting will return next week. Due to the recent layoff at my company, I'm going to have plenty of time to ...
AVEO and Biogen Team Up
AVEO and Biogen announced a strategic collaboration for the development and commercialization of AVEO’s novel discovery-stage ErbB3-targeted antibodies for the potential treatment of cancer and ...
CV Tells Astellas to Shove It: Looks to Gilead
All this talk by Astellas about taking over the board of directors and taking the decisision to the shareholders seems it may have been in ...
Mega-mergers Are Not Good For Business
There's an article this morning on Bloomberg insinuating that the Pfizer/Wyeth, Genentech/Roche and now Merck/Schering-Plough mergers have placed pressure on the remaining members of ...
Merck to Buy Schering-Plough for $41.1 Billion Cash and Stock Deal
Not to be outdone by Pfizer / Wyeth, Merck and Schering-Plough announced that their Boards of Directors have unanimously approved a merger. Schering has ...
Symphogen and Origen Collaborate Will Develop Transgenic Chickens Capable Of…..
[caption id="" align="alignleft" width="200" caption="From hddod onFlickr"][/caption] Sounds ominous, no? Symphogen and Origen announced a collaboration to develop a transgenic chicken capable of producing human antibodies ...
Proteon Therapeutics Has A Big Day
Proteon Therapeutics announced it has successfully completed a $38 million Series B equity financing, started a Phase 1/2 clinical trial with its lead product, PRT-201, ...
Vertex to Buy Hepatitis C Drug Developer ViroChem for $375M
Vertex, which is developing the hepatitis C virus (HCV) protease inhibitor telaprevir, will add two polymerase inhibitors to its HCV drug development portfolio through an ...
They Weren’t Bluffing: Astellas Lauches Tender Offer for CV Therapeutics
Astellas announced that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced a cash tender offer for all outstanding shares of common stock of CV Therapeutics ...
Heptares Secures $30M in Series A Funding
Heptares Therapeutics, the drug discovery company focused on drugs targeting G-protein-coupled receptors (GPCRs), annnouced it has raised $30M (GBP21M) of equity finance in a successful ...
Lilly Taps NeuroSearch For Preclinical Discovery Deal
Just a week after NeuroSearch failed a phase II pain trial (ABT-894), they've inked a collaboration which will focus on new CNS ...
Orexo Licenses Development for OX17 to Mystery Suitor
Orexo has signed an exclusive development agreement with "a large healthcare company", providing for joint development within Orexo’s OX17 program for gastroesophageal reflux disease (GERD), ...












Recent Comments